Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
0.7191
+0.0192 (2.74%)
At close: May 9, 2025, 4:00 PM
0.7092
-0.0099 (-1.38%)
After-hours: May 9, 2025, 4:00 PM EDT
Ironwood Pharmaceuticals Stock Forecast
IRWD's stock price has decreased by -91.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ironwood Pharmaceuticals stock have an average target of 4.94, with a low estimate of 0.70 and a high estimate of 14. The average target predicts an increase of 586.97% from the current stock price of 0.72.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | +39.06% | Apr 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $8 → $0.7 | Strong Buy → Hold | Downgrades | $8 → $0.7 | -2.66% | Apr 15, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +39.06% | Apr 14, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $23 → $14 | Buy | Maintains | $23 → $14 | +1,846.88% | Jan 30, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +1,012.50% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
274.58M
from 351.41M
Decreased by -21.86%
Revenue Next Year
257.11M
from 274.58M
Decreased by -6.36%
EPS This Year
0.17
from 0.01
Increased by 2,899.88%
EPS Next Year
0.19
from 0.17
Increased by 16.80%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 287.5M | 289.2M | 237.3M | ||
| Avg | 274.6M | 257.1M | 207.6M | ||
| Low | 258.7M | 219.5M | 177.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -18.2% | 5.3% | -7.7% | ||
| Avg | -21.9% | -6.4% | -19.3% | ||
| Low | -26.4% | -20.1% | -31.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.23 | 0.42 | 0.15 | ||
| Avg | 0.17 | 0.19 | 0.04 | ||
| Low | 0.10 | 0.03 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4,038.5% | 150.6% | -24.1% | ||
| Avg | 2,899.9% | 16.8% | -78.9% | ||
| Low | 1,671.8% | -82.3% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.